Study shows real-world benefits of onasemnogene abeparvovec in younger SMA patients

Lena-Luise Becker discusses findings from a real-world study showing that spinal muscular atrophy patients younger than 8 months of age are the most likely to benefit from onasemnogene abeparvovec, while those older than 24 months have a lower likelihood of treatment response and a higher risk for side effects (4:22).